An independent panel of Experts advising the Food and Drug Administration will review data on Moderna's coronavirus vaccine booster on Thursday and Johnson & Johnson's on Friday. Each day will end with a panel vote on whether to recommend a recall. emergency clearance for this recall for recipients of this vaccine.
So what happens after the panel vote? 'other steps to the FDA, then steps to the Centers for Disease Control and Prevention, and the process ends with the States. Here's how it breaks downe:
The FDA, a federal agency of the Department of Health and Human Services which controls and supervises medicines and other items related to public health, echoes the recommendation of the advisory committee, which includes the question of who should be eligible. The votes of the advisory committee are not binding, but the F.D.A. usually follows them.
The most senior official of the FDA - its acting commissioner, Dr. Janet Woodcock - issues the agency's final decision on whether to authorize boosters and for whom. Such decisions are usually made a few days after the meetings of the advisory committee.
Image Dr. Rochelle P. Walensky, CDC director , publishes guidance for states and the general public. Credit ... Stefani Reynolds for Hfrance.fr
An advisory group to the Centers for Disease Control and Prevention, the US public health agency, is reviewing the FDA decision. Thursday and Friday of next week, that panel is due to meet and vote on its recommendations concerning boosters.
The CDC takes into account the recommendations of this panel, and the agency director, Dr Rochelle P. Walensky, issues agency guidelines on whether to use boosters and who should be eligible. Boards have great influence on states, physicians, pharmacies and other health care facilities, and the general public. As with the FDA process, the panel's recommendations are not binding, but the CDC generally follows them.
However, there was a rare exception last month: when a CDC advisory committee rejected the FDA recommendation that frontline workers be included among those eligible for the Pfizer-BioNTech booster , Dr. Walensky has overtaken his own agency advisers and sided with the FDA
State health services generally follow CDC recommendations In the case of the Pfizer-BioNTech recall, injections began to be widely administered immediately after Dr. Walensky announced CDC guidelines to allow them to people over 65, patients in nursing homes and other institutional settings, those with underlying health conditions, and frontline workers.